2022 AAVPT Annual Business Meeting Minutes


Approval of minutes from 2021

Dr. Fajt made a motion to approve the minutes; seconded by Dr. Davis. Unanimous approval granted and motion was approved.

Biennial Meeting Update and President’s report

The dates/place of the next Biennial Meeting were announced. The meeting will be held May 21 to 24, 2023 in Bethesda, MD. Additional details will be announced as they become available. Award winners for Research, Service, Teaching and the Lloyd E Davis Memorial award were announced – see President’s report for additional details.

Secretary’s Report

A recap of the online Research Symposium was given. More than 50 people from 3 different continents attended. Winners have been announced (see Secretary’s report) and links to the winning presentations are available on the AAVPT homepage (aavpt.org). Two thousand dollars in prize money was handed out to our student winners. Additional links to the morning and afternoon presentation sessions, as well as the award ceremony and a presentation by our Research award winner (J. Mochel) are available at:

https://www.aavpt.org/page/SymposiumWorkshops

Treasurer’s Report

Due to a security breach, the checking account was down $7,455 which is close to the amount typically requested for annual website hosting fees. That checking account was closed and a new account opened. Ten thousand dollars was transferred from the investment account to the new checking account to cover expenses and losses. See Treasurer’s report for additional details.

Comptroller’s Report

Dr. Brown was unavailable for the meeting, but Dr. Wittenburg was able to give a summary of the accounts. The accounts are performing better than expected based on the market. Taxes have been filed. Dr. Brown recommends maintaining the investments at $125,000 with a $30-35,000 donation to VPRF. **At the meeting, it was unknown if that recommendation would be affected by the $10,000 transfer to checking. Further discussion with Dr. Brown said it will not. The EC voted to donate $30,000 to VPRF for this year’s research grant cycle.**
VPRF Grants

Dr. Owen has submitted an annual report. She stressed the need to make sure that anyone submitting will click the final ‘Submit’ button as last year, there were grants left in the ‘in progress/draft’ stage. VPRF now has a new website (https://www.vprfonline.org/donate). Dr. Brown has been made a board member and will be involved in fundraising efforts.

Dr. Owens asked that a vote on the VPRF donation from AAVPT be added to the agenda. Dr. Hare responded that it would be added to the next EC meeting agenda.

MDR1 Research update

Dr. Owens presented an update from the meeting held in 2018 regarding replacing the dog model with a mouse model. A committee was formed as part of AHI. They are currently working through draft proposals and studies should be available in late 2022/early 2023. The goal will be to publish these studies. See report for more details.

Drs. Fajt and Baynes applauded the efforts of the committee and suggested that the collaborative process may be published to guide future efforts. Dr. Owens thanked them and stated the transgenic mice were currently at CVM and the colony will soon be established and the studies will happen. This provides an excellent framework for future collaborations.

JVPT Report

Dr. Mealey was not present, but a standard report has been submitted.

Call to Accept Reports

Dr. Fajt made a motion to accept all reports as submitted; Dr. Wittenburg seconded. All were in favor.

Call for Nominations for Elections

Elections will be held next year and new officers announced at the Biennial. Anyone wishing to run for office, or serve on or Chair an AAVPT committee can contact Dr. Hare or Dr. Davis.

Call for Walk-in Items

No walk-in items were discussed.

Call to Adjourn

Dr. Hunter made a motion to adjourn the meeting, Dr. Fajt seconded. All were in favor.
AGENDA
AAVPT Annual Business Meeting
Thursday, August 4, 2022
2-4 pm EDT

Join Zoom Meeting
https://us02web.zoom.us/j/83964373763

Meeting ID: 839 6437 3763
One tap mobile
+13126266799,,83964373763# US (Chicago)
+16469313860,,83964373763# US

Dial by your location
  +1 312 626 6799 US (Chicago)
  +1 646 931 3860 US
  +1 929 436 2866 US (New York)
  +1 301 715 8592 US (Washington DC)
  +1 346 248 7799 US (Houston)
  +1 386 347 5053 US
  +1 564 217 2000 US
  +1 669 444 9171 US
  +1 669 900 6833 US (San Jose)
  +1 253 215 8782 US (Tacoma)

Welcome (Jonathan Hare)
Approve minutes from 2021 Annual Business Meeting
Reports
  22nd Biennial in 2023 (Jonathan Hare/Michela Cantiello)
  President (Jonathan Hare)
  Secretary (Jen Davis)
  Website Update
  Treasurer/Comptroller (Luke Wittenburg, Scott Brown (in absentia))
Veterinary Pharmacology Research Foundation (Jane Owens)
AHI MDR Subcommittee update to AAVPT 2022 (Jane Owens)
Journal of Veterinary Pharmacology and Therapeutics (Katrina Mealey)
Other reports
Vote to accept reports
Nominations for officers
Walk-in Items
Close meeting
President’s Report

I hope this finds you all well! As I write this, I am recovering from COVID – a singular joy that I would not wish on anyone but I fear has afflicted many of us! Indeed, inasmuch as COVID has shaped our lives over the past two years, it has also impacted the Academy.

We valiantly attempted to hold our Biennial Symposium in 2021 and again in 2022, only to be thwarted on both occasions. Some of you have, no doubt, attended in-person CE this year and might be curious to know why we have taken a pass on our meeting?

We need at least a six-month runway to organize the meeting. People need to make travel plans and get leave organized; speakers need time to get their presentations set; and, last but not least, our hotel commitments start to become real (as in, not-refundable) about that time. Furthermore, in the late fall of 2021 we were climbing the peaks of the Omicron variant.

We had to pull the plug and we were sorry to do so. But we’re at our foundation, a science-based organization, so we listened to the science.

Luckily, however, we have Jen Davis! Jen proceeded to make a silk purse out of a sow’s ear and spearheaded our online student symposium (see her report for more details). Those of us who attended were treated to some truly excellent presentations.

In addition, we decided to grant our biennial awards. The winners were:

- Lloyd E. Davis Memorial Award: Dr. Stephen Sundlof
- Service Award: Dr. Anthony Lucas
- Teaching Award: Dr. Duncan Ferguson
- Research Award: Dr. Jonathan Mochel

Jon gave an absorbing overview of his research at the study symposium. Stephen has agreed to give his LE Davis presentation at the 2023 Biennial.

Speaking of which, the 2023 Biennial will be held May 21 to 24, 2023 in Bethesda. Michela Cantiello (your president elect) and I are co-chairs. If you’d like to help out (please!!) drop either of us a line. Assuming the Bethesda Marriott is still speaking to us (after bailing on them twice) we’ll hold it there, but stay tuned for confirmation!

Stay healthy,

Jonathan Hare, DVM, PhD, Dipl ACVCP
President, AAVPT
By the end of 2021, we had 126 members. Member renewals were due in a large part to the efforts of our new executive assistant Kate Niemuller. So far in 2022, we have had 34 new and renewing members. We have added two new options for renewal this year – a 2 yr Fellow and a 2 yr Associate Fellow membership. This will allow members to renew once and be all paid up for the Biennial cycle (assuming we can go back to every other year). Bear in mind that not all companies and Universities will reimburse for a 2 year period. The Biennial in 2019 resulted in or largest membership numbers within the last 6 years (see below). If you know of anyone interested in veterinary pharmacology who is not already a member, please direct them to the website and encourage them to become members.

We are also still soliciting calls for upgraded membership. If you know someone deserving of Fellow Membership or Distinguished Fellow Membership, please feel free to nominate them. Self-nominations are accepted with appropriate references.

If you have not paid your annual dues yet, please login to the website (aavpt.org) to renew your membership and update your information. Otherwise, look for another membership renewal reminder at the end of the year. We are continuing to streamline the process of dues renewal and notification. Remember, members can renew their memberships, subscribe to the Journal of Veterinary Pharmacology and Therapeutics at a reduced rate, as well as donate to AAVPT and VPRF year-round, rather than just once a year.

Elections will be held next year, with new officers announced at the next Biennial (SAVE THE DATES: MAY 21-24, 2023). Open positions will include two members of the Executive Council, Treasurer and President-Elect. If you are interested in becoming more active in AAVPT and would like to join a committee, please let me know. We need the help of all our members if we want our organization to grow and continue to be relevant. Current active committees listed in the bylaws include:

1. Finance and Budget Committee
2. Membership and Bylaws Committee (current: Boothe)
3. Program Committee (current: Cantiello)
4. Education Committee (current: Fajt)
5. Awards Committee
6. AAVPT Newsletter Committee (current: Davis)

We have made a concerted effort to include new members in our listserv and to update the information on our current members. If your email has changed, please send a note to aavptsec@gmail.com and I will fix it for you!

Finally, I would like to thank everyone that attended and participated in our online symposium. We had 12 student presenters from 3 continents and up to 53 attendees at a time. The quality of the presentations was outstanding. Proceedings with abstracts and recordings of the presentations are available on the website (AAVPT.org > Resources > Symposia, Workshops & Webinars). Winner’s presentations are also linked directly on the home page. Our winners included:
Dariyan Springfield ($1000)
JD Foster ($500)
Melissa Mercer ($500)

Please congratulate them when you see them!

The recording of the awards presentation is also available on the website, including a presentation by Dr. Mochel on his research focus titled ‘Modeling and Simulation: a Tool for Optimizing Dosing Decisions in Veterinary Medicine’. Congratulations to these very deserving AAVPT members. Please forward any nominations for 2023 awards to aavptsec@gmail.com or our awards committee – also please volunteer to chair our awards committee!!!

Thanks again and I am looking forward to seeing all of you at the Biennial, **MAY 21-24, 2023 in Bethesda, MD!**

Jennifer L Davis, DVM, PhD, DACVCP, DACVIM
Treasurer’s Report

We have a present balance of $10,129.50 in our account. We have a new account number due to fraudulent activity requiring the old account to be closed and a new one opened up. I have changed bank information with AffiniPay for online dues payments.

Revenue since last report (August 1st, 2021) as follows:

- $5,100 from membership fees (this includes amounts that were added to dues payments for VPRF donations of $1,175).

Expenses since last report as follows:

- $1,063.87 in bank, credit card, corporation registration, P.O. Box, Zoom account fees
- $4,248.99 for website hosting (YourMembership)
- $1,175 in VPRF donations
- $2,000 in poster presentation awards (still awaiting one $500 check to clear).
- $7,455 in fraudulent ACH payments made. Between May 27th and June 13th there were four ACH payments that I made based on emails that I received that appeared to come from Jonathan Hare’s email address (via iPhone). These requests were for payment to a “new vendor” for “Operating Expenses of Networking Activities, Website hosting and program services.” As the requests came shortly after the online poster symposium I assumed the request had something to do with costs associated with having the online symposium. After the first payment, a confirmation of payment receipt was sent to me with a request to pay for a year of service with the new vendor. I requested invoices for these payments as Jonathan has previously asked me to send payments but would provide an invoice. I was told that all of the invoices would be sent together at the end of the day I requested them. After these payments were made, an email again appeared to come from Jonathan requesting an additional payment of $5,000 that was approved by “the board members” for rebuilding the website. At this point I went back to an old email that I had from Jonathan (the real one) and asked him if these requests were really from him...they were not! Upon then contacting the bank, they suggested that I close the account because our bank info would be available to the people impersonating Jonathan through the ACH payments. A new account was set up and I contacted Scott Brown for a transfer from the investment account to keep the “healthy” balance that we generally maintain in the checking account.

Investment accounts:

- One-time transfer of $10,000 was made from investment account into new Chase bank account.

Luke Wittenburg, DVM, PhD, DACVCP
Treasurer

July 26, 2022
The Raymond James AAVPT investment fund has a current balance (May 31, 2022) of $171,587.68, down from the balance at the start 2021 of $187,664.58. This decline is substantially less than the downturn of the major market indicators (S&P, Dow Jones industrial average, or NASDAQ), and reflects the market changes and excellent management of the fund by the financial advisor.

The following is the breakdown of the fund from May 31, 2021 to May 31, 2022.

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning balance (May 31, 2021):</td>
<td>$169,690.68</td>
</tr>
<tr>
<td>Income:</td>
<td>$11,260.15</td>
</tr>
<tr>
<td>Withdrawals (transfers to VPRF):</td>
<td>$0.00</td>
</tr>
<tr>
<td>Change in value:</td>
<td>$17,973.90</td>
</tr>
<tr>
<td>Balance (December 2021):</td>
<td>$187,664.58</td>
</tr>
<tr>
<td>2021 Dollar Weighted Performance</td>
<td>5.38%</td>
</tr>
<tr>
<td>Income (2022 YTD)</td>
<td>$645.45</td>
</tr>
<tr>
<td>Change in value (2022 YTD)</td>
<td>($16,722.35)</td>
</tr>
<tr>
<td>2022 Dollar Weighted Performance (YTD)</td>
<td>(8.57%)</td>
</tr>
<tr>
<td>Ending Balance (May 31, 2022)</td>
<td>$171,587.68</td>
</tr>
</tbody>
</table>

The Comptroller recommends providing additional donations to the VPRF over the next 4-6 months in the range of $30,000-$35,000 to bring the balance of the investment fund to approximately $125,000. This maintains a reserve needed for execution and funding of long-range planning and strategy recommendations. Considering the volatility of the market, keeping this value above $125,000 seems prudent at this time.

The Comptroller also filed Non-Profit Federal Income Tax forms for FY 2021 in May 2022 (electronic correspondence on file).

Respectfully submitted,
Scott Brown, DVM, PhD, Dipl ACVCP
AAPVT Comptroller
The Foundation was formed in 2007 to provide grant funding to support research into new and currently approved medications for combating diseases of companion and food animals, projects that ensure the safety of food products from treated livestock, and training programs for veterinary pharmacologists. The research support from the VPRF has advanced veterinary pharmacology, particularly in areas of unmet needs in veterinary medicine.

The first call for proposals went out in November 2009. To date, VPRF has funded over $400,000 in support of veterinary pharmacology research. The Foundation has evaluated over 350 proposals and awarded 23 research grants with 13 funded for dogs, 5 for cats, 1 for swine, and 2 each for equine and dairy cattle. Please see Appendix I for a complete listing of all awarded grants, including the 2021 grants awarded to Drs. Grobman and Hamer.

In 2022, VPRF will continue the strategic partnership with the American Veterinary Medical Foundation (AVMF) to provide the much-needed infrastructure to support proposals, reviews, and grant administration. The Board has approved a 2022 budget to fund up to $15,000 in grants investigating the pharmacokinetics of medications in animals and up to $30,000 to fund grants for general pharmacology studies of drugs in animals.

The 2022 call for proposals will go out on July 15th and will close on September 15th. A final funding decision is expected in January 2023.

For 2022, we are pleased to announce that we will honor two outstanding pharmacologists who we have recently lost. We are proud to honor these remarkable pharmacologists and hope you will consider donating to continue their legacy in the field that they so loved.

- 2022 Honorary Lloyd E. Davis Pharmacology Grant
- 2022 Honorary Ralph Claxton Pharmacokinetic Grant

AAVPT and individual ACVCP and AAVPT members are the largest sponsors of VPRF. As of June 30, 2022, VPRF has a liquid asset value of $157,425. Total revenue for the year decreased to $1,175 as we have not yet received AAVPT’s annual pledge given that the annual meeting is later this year and we recently changed our accounting period to correspond to the calendar year. Revenue consisted of individual contributions, and we remain grateful for these donations. Please see Appendix II for the financial report from Dr. Gingerich.
VPRF has recently launched a new website where we will share the latest information on our grant programs and accept donations. We owe many thanks to Katie Palmatier for her excellent talents in creating this new site and for her tireless support of VPRF.

The VPRF board of directors currently includes Jane Owens (President, representing ACVCP), Anthony Lucas (Secretary, representing AAVPT), Dan Gingerich (Treasurer, representing AAVPT), Joe Gloyd (representing AAVPT), Mark Papich (representing ACVCP), Virginia Fajt (representing AAVPT), and Jay Donecker (representing AAVPT). In the summer of 2022, we were pleased to add Scott Brown to our Board of Directors. Scott has held many leadership positions in R&D within the pharmaceutical industry including Upjohn Animal Health, Pharmacia Animal Health, Pfizer Animal Health, and Zoetis, where he recently retired as the Vice President of External Innovation. In this new VPRF Board position, Scott will focus on enhancing VPRF’s fundraising strategies and organizational effectiveness. Please join us in welcoming Scott to the VPRF Board.

VPRF greatly appreciates the continued support and generosity of AAVPT as we work toward our goal of advancing the field of veterinary pharmacology.

Respectfully submitted, Jane G. Owens, President VPRF
Appendix I

VPRF Grant History

2010

The first call for proposals yielded over 30 research proposals for evaluation by the Scientific Review Committee. The first VPRF grant was awarded in June 2010 to Drs. Kenneth Simpson, Melanie Craven, and Belgin Dogan from Cornell University for the development of a novel amikacin delivery method for treatment of E. coli associated with Granulomatous Colitis of Boxer dogs. The researchers received approximately $18,000 for this important work.

2011

In 2011, 12 veterinary pharmacology research proposals were submitted. In November of 2011, a grant of nearly $18,000 was awarded to Drs. Butch KuKanich and Kate KuKanich from Kansas State University for a study to determine the effect of CYP inhibition on tramadol disposition and pharmacological effects in dogs.

2012

In 2012, a total of 20 veterinary pharmacology research proposals were received. Of these, two proposals were selected for funding. Drs. Chen Gilor and Christopher Adin of the Veterinary Clinical Sciences Department at the Ohio State University received approximately $16,000 in funding for evaluating Exenatide extended release in cats. Approximately $4000 was awarded to Drs. Jennifer Myers, Janice Bright, Christopher Orton, Daniel Gustafson and Christine Swardson Olver from the College of Veterinary Medicine & Biomedical Sciences, Colorado State University for evaluation of the pharmacokinetics and pharmacodynamics of Apibaxin in cats. These researchers also received additional funding from ACVIMF for this work.

2013

In 2013, there were 13 grant proposals for evaluation by the Scientific Review Committee. The 2013 Grant was awarded to Drs. Dawn Boothe and Jacqueline Gimmler from the Auburn College of Veterinary Medicine for work to establish terbinafine doses for treatment of canine Malassezia infection. This project was co-funded from the American College of Veterinary Dermatology and the investigators received approximately $14,500 from VPRF.

2014

In 2014, there were 19 grant proposals for evaluation by the Scientific Review Committee. The 2014 Grant was awarded to Dr. Lauren Trepanier of the University of Wisconsin-Madison School of Veterinary Medicine for work to investigate the Genetic risk for cyclophosphamide toxicity in dogs. The investigator received approximately $17,500 from VPRF.
2015

In 2015, there were 25 grant proposals for evaluation by the Scientific Review Committee. This was a landmark year for VPRF as the organization awarded three grants:

- Dr. Sofia Cerdá-González from Cornell University received approximately $12,700 from VPRF for work to investigate the efficacy of maropitant (Cerenia®) as an adjunct analgesic in dogs.
- Dr. Andrew Mackin from Mississippi State University received approximately $18,000 from VPRF for the pharmacodynamic evaluation of mycophenolate in the dog.
- Drs. M. Katherine Tolbert and Shelly Olin from the University of Tennessee received approximately $15,140 from VPRF for a project to evaluate whether acid suppressants are indicated in cats with chronic kidney disease.

2016

In 2016, there were 39 grant proposals for evaluation by the Scientific Review Committee. This was a record number of submissions and the foundation selected two grants for funding:

- Dr. Claire Fellman from Tufts University received $26,223 in funding for the Pharmacokinetic/Pharmacodynamic Assessment of Differential Responses to Cyclosporine in Atopic Dogs.
- Dr. Katrina R. Viviano, from University of Wisconsin-Madison received $19,280 in funding for a project to evaluate C-Reactive Protein as a Therapeutic Biomarker for Canine Aspiration Pneumonia.

2017

In 2017, there were 52 grant proposals for evaluation by the Scientific Review Committee. This was a record number of submissions and the foundation selected one pharmacokinetic grant and one pharmacology grant for funding:

- Dr. Derek Foster received nearly $30,000 for the Veterinary Pharmacology Research Grant. This work entailed the continuous sampling of the bovine udder by ultrafiltration to assess the pharmacokinetics and pharmacodynamics of intramammary ceftiofur.
- Dr. Duncan X. Lascelles received nearly $15,000 for the Veterinary Pharmacokinetic Research Grant. Dr. Lascelles’ research focuses on the pharmacokinetics of gabapentin in cats by three routes of administration.

2018

In 2018, there were 49 grant proposals for evaluation by the Scientific Review Committee. The foundation selected two pharmacokinetic grants and one pharmacology grant for funding. The 2018 pharmacokinetic grant was named in honor of Dr. Brian Riviere who was the son of Dr. Jim Riviere, Emeritus Professor at North Carolina State University and Kansas State University, one of the pioneers in veterinary pharmacokinetics. His son Brian, was a pharmacist who died suddenly on June 28, 2017, at age 30, due to health complications. Because of their shared interest for pharmacology, the Veterinary Pharmacology Research Foundation has named this research award in honor and memory of Jim’s son Brian.
• Dr. Lauren Trepanier, professor and assistant dean of clinical and translational research at the University of Wisconsin-Madison School of Veterinary Medicine, was the recipient of the Veterinary Pharmacology Research Grant of nearly $12,000 for work to discover why individual dogs respond differently to the drugs azathioprine, cyclophosphamide, cisplatin, lomustine, amiodarone and chlorambucil.
• Dr. John Thomason, associate professor of small animal internal medicine in the Department of Clinical Sciences at Mississippi State College of Veterinary Medicine received nearly $15,000 for research on population pharmacokinetics of subcutaneous enoxaparin in hypercoagulable dogs.
• Dr. Jonathan Foster, internist, Dialysis, Internal Medicine at Friendship Hospital for Animals in Washington, D.C., who was awarded nearly $12,000 for a research on the population pharmacokinetic analysis of enrofloxacin and its active metabolite ciprofloxacin following intravenous injection in cats with reduced kidney function.

2019

In 2019, there were 30 grant proposals for evaluation by the Scientific Review Committee. The foundation selected the following grants for funding:

• Dr. Kara Lascola, associate professor of equine internal medicine, department of clinical sciences at Auburn University’s College of Veterinary Medicine, received the 2019 Veterinary Pharmacokinetic Research Grant. Dr. Lascola’s proposal focused on the evaluation of the pharmacokinetics of nebulized glycopyrrolate administered to asthmatic horses.
• Dr. Monique Pairis-Garcia, associate professor of global production animal welfare, department of population health and pathobiology at North Carolina State University’s College of Veterinary Medicine received the 2019 Veterinary Pharmacology Research Grant. Dr. Pairis-Garcia’s research aims to identify practical pharmaceutical approaches to mitigate castration pain on commercial swine farms.

2020

In 2020, there were 33 grant proposals for evaluation by the Scientific Review Committee. The foundation selected one pharmacokinetic grant and one pharmacology grant for funding:

• Dr. Amy McLean, Assistant Professor of Teaching Equine Science, UC Davis Animal Science World Donkey Breeds Project received the 2020 Veterinary Pharmacokinetic Research Grant. Dr. McLean’s research is focused on comparing the pharmacokinetics of three flunixin meglumine formulations in donkeys.
• Dr. Andras Komaromy, Professor, Comparative Ophthalmology, Department of Small Animal Clinical Sciences, Michigan State University received the 2020 Veterinary Pharmacology Research Grant. Dr. Komaromy’s research is focused on the Safety and efficacy of topically administered latanoprostene bunod (Vyzulta™) in glaucomatous dogs with ADAMTS10-open-angle glaucoma.

Also in 2020, VPRF partnered with the American College of Veterinary Clinical Pharmacology (ACVCP) to provide a new grant focused on ACVCP Residents. We are grateful to ACVCP for providing $20,000 in funding for this grant as well as additional funding to administer the grant. The ACVCP Resident Grant moved VPRF one step closer to our goal of providing training programs for veterinary pharmacologists.
• Dr. Brent Credille, Associate Professor Food Animal Health and Management Program, Department of Population Health, College of Veterinary Medicine University of Georgia was
selected to receive the first ever ACVCP Resident Grant for his project entitled “Disposition of Ampicillin Trihydrate in Healthy Calves and Calves Infected with Mannheimia haemolytica.”

2021

In 2021, there were 29 grant proposals for evaluation by the Scientific Review Committee. The foundation selected two pharmacology grants for funding:

- Dr. Megan Grobman, Assistant Professor of Small Animal Internal Medicine at Auburn University College of Veterinary Medicine, received funding to evaluate the impact of single-dose administration of, trazadone on endogenous ACTH and cortisol in healthy dogs.

- Dr. Sarah A. Hamer, Associate Professor of Epidemiology at the Texas A&M College of Veterinary Medicine & Biomedical Sciences (CVMBS), received funding for a study to evaluate the effectiveness of benznidazole to improve clinical outcomes in client-owned, naturally-infected dogs with Chagas disease, a potentially life-threatening disease of people, dogs, and other animals.

Appendix II

Turtle Creek Biostatistical Services
2219 Wilmington Road, Lebanon, OH 45036
Phone: 513-313-5901
dangingerich60@gmail.com

TO: Jane Owens, President Veterinary Pharmacology Research Foundation (VPRF)

FROM: Dan Gingerich

DATE: June 30, 2022

SUBJECT: VPRF Treasurer’s Report, 2022

Please note that this is an awkward time for a financial update due to the fact that Veterinary Pharmacology Research Foundation (VPRF) has changed its accounting period to January 1 through December 31. This update covers VPRF finances from December 31, 2021, to June 30, 2022.

- Liquid assets on December 31, 2021 $229,174
- Individual donations $1,175
- Expenses ($324)
- 2021 Grant expense ($44,900)
- Returns on investments ($27,700)
- Liquid assets as of June 30, 2022 $157,425

As of this date VPRF has a liquid asset value of $157,425. 2021 grants in the amount of $44,900 have been awarded, administered by AVMF. Individual donations totaling $1,175 through AAVPT were received, but we have not yet received AAVPT’s annual pledge. Investment returns are strongly negative, down at an internal return rate of -22% thus far due to the overall downturn in the market. However, VPRF remains financially healthy and we anticipate making further research awards this year.

Attached are the details of our current finances.
<table>
<thead>
<tr>
<th>Date</th>
<th>Class A Shares</th>
<th>NAV</th>
<th>Shares</th>
<th>Current Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>31-Dec-22</td>
<td>American Balanced Fund [AKR]</td>
<td>$28.57</td>
<td>1,655.06</td>
<td>$48,142.22</td>
</tr>
<tr>
<td></td>
<td>Fund Transactions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31-Jan-22</td>
<td>American Balanced Fund [AKAUX]</td>
<td>$77,002.26</td>
<td>$14,500.00</td>
<td>$1,175.00</td>
</tr>
<tr>
<td></td>
<td>Capital Income Builder (KMBX)</td>
<td>$40,318.57</td>
<td>$14,500.00</td>
<td>$1,175.00</td>
</tr>
<tr>
<td>30-May-22</td>
<td>Gay World Growth &amp; Income [GWGIQ]</td>
<td>$29,332.43</td>
<td>$14,500.00</td>
<td>$1,175.00</td>
</tr>
<tr>
<td></td>
<td>Capital World Growth and Income Fund [GWGEX]</td>
<td>$40,480.22</td>
<td>$14,500.00</td>
<td>$1,175.00</td>
</tr>
<tr>
<td>30-Jun-22</td>
<td>Fundamental Investors [AMOEX]</td>
<td>$132,063.01</td>
<td>$14,500.00</td>
<td>$1,175.00</td>
</tr>
<tr>
<td></td>
<td>The Income Fund of America [AMOIX]</td>
<td>$40,287.22</td>
<td>$14,500.00</td>
<td>$1,175.00</td>
</tr>
<tr>
<td>30-Jul-22</td>
<td>$228,173.02</td>
<td>($269.38)</td>
<td>($2,400.00)</td>
<td>$1,175.00</td>
</tr>
<tr>
<td>30-Aug-22</td>
<td>$151,438.06</td>
<td>($42,735.06)</td>
<td>($3,200.00)</td>
<td>$1,175.00</td>
</tr>
<tr>
<td>31-Sept-22</td>
<td>$151,438.06</td>
<td>($42,735.06)</td>
<td>($3,200.00)</td>
<td>$1,175.00</td>
</tr>
</tbody>
</table>

**Irr** - The Income Fund of America (AMOIX)

**View Returns**

- **AIPS Individual donations** | $1,175.00 | **% cash** | 1.79%
- **Katy Gamp Powers** | $56,98 |

**Total Account Value**

- **Bank** | $7,766.91
- **Investments** | $154,657.74
- **AIPS Individual donations** | $1,175.00
- **Katy Gamp Powers** | $56,98 |

**Investments** | $154,657.74

**Total Account Value** | $162,424.65

**AIPS Individual donations** | $1,175.00

**Katy Gamp Powers** | $56,98 |

**Irr** - The Income Fund of America (AMOIX)

**View Returns**
AAVPT update on the Collaboration of Several Animal Health Institute Member Companies and FDA-CVM to Qualify a Transgenic Mouse Model to Replace Collie Safety Studies

Scientific Background

Due to economic limitations associated with veterinary drug development, the FDA must rely upon very limited data sets for establishing product safety and effectiveness. This problem is further compounded by the limited numbers of Collies and research sites available to determine the safety of novel avermectin-class heartworm drugs. As avermectins are known to cause Central Nervous System (CNS) toxicities in herding-type dogs as well as other breeds, all new avermectins must be examined in a “Collie Safety Study” to determine whether they will cause CNS toxicities. The increased sensitivity to CNS toxicities in these dogs is due to a genetic defect in their ATP-binding cassette, sub-family B member 1 (ABCB1) gene. The ABCB1 gene encodes for P-glycoprotein (P-gp), a transmembrane efflux protein that affects the absorption, distribution and elimination of certain drugs. Without this protein pump, avermectins are able to more readily access the CNS to cause toxicity. Two novel alternative transgenic mouse models (Yancy 1 and Yancy 2) have been created to contain the mutant and wild type canine P-gp protein and have been published by FDA-CVM. This new transgenic mouse model has the potential to reduce the need for Collie safety assessments of new avermectin-class drugs, and also provide safety information of other P-gp substrates.

Research Goal

The overarching goal is to generate sufficient data utilizing the transgenic mouse model to be confident that it could predict the toxic potential of P-gp substrates in dogs with the ABCB1 mutation. By qualifying the mouse model with a number of P-pg substrates, it could replace the use of ivermectin-sensitive Collies needed to assess CNS toxicity.

Innovation and Collaboration

As an innovative collaboration between several major animal health companies, Washington State University and the Food and Drug Administration, this work is a novel approach to define alternative test methods to assess clinical safety in dogs carrying the ABCB1 genetic defect.

Benefits

Importantly, this work is in line with commitments to reduce, refine and replace animal use in research. Successful validation would have significant animal welfare advantages over current practice of using Collies to assess the CNS effects of avermectins. Further, a laboratory model in rodents would provide an opportunity to refine the methods to assess CNS toxicity to be more reliable, repeatable, and objective.

Work to date

In 2018, the Animal Health industry joined with the American Academy of Veterinary Pharmacology and Therapeutics (AAVPT) to host a 2 day workshop on Issues and Alternatives for Safety Assessment of
Macrocyclic Lactones in P-gp Deficient Dogs. The Animal Health Institute (AHI) served as the convening organization. Approximately 50 attendees participated in the workshop. CVM actively participated in the planning of the session and participated in the workshop. Workshop participants strongly supported the concept of CVM and industry working together to validate a mouse model.

AHI served as the facilitator to continue the work proposed by the workshop participants. An AHI subcommittee was formed in 2020, comprised of representatives from industry, CVM, and academia, to develop a formal collaboration to validate/qualify the CVM transgenic mouse model to assess neurotoxicity in MDR-1 deficient dogs. The subcommittee has accomplished several important goals to date including:

- Define the legal framework of a collaborative agreement to work between CVM/Industry/academia.
- Define data needed for industry and CVM and to develop a data sharing framework
- Agree on test compounds and study design to qualify the transgenic mouse model
- Ensure the proposed model addresses CVM expectations.

The subcommittee has agreed to use a Research Collaboration Agreement (RCA) between animal health companies, academia and FDA. This agreement is in the final stages of review and negotiation. Studies are in the final design stage and will use multiple compounds known to be substrates for canine P-gp to validate/qualify this model as a replacement for studies in MDR-1 deficient Collies. Specifically, the study will use 3 positive controls (ivermectin, moxidectin and loperamide) that are P-gp substrates with known CNS effects in MDR-1 deficient dogs and a negative control (cyclosporin) that is a substrate lacking CNS toxicity

**Next Steps**

- Finalize RCAs
- Re-establish colonies of Yancy 1 and Yancy 2 transgenic mice
- Finalize study protocols
- Initiate studies in late 2022
- Complete in vivo work in 2023
- Analyze data, publish results
<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lea</td>
<td>Cranford</td>
</tr>
<tr>
<td>Rachel</td>
<td>Cumberbatch</td>
</tr>
<tr>
<td>Cyril</td>
<td>Desevaux</td>
</tr>
<tr>
<td>Elaine</td>
<td>Freeman</td>
</tr>
<tr>
<td>Mark</td>
<td>Heit</td>
</tr>
<tr>
<td>Scott</td>
<td>Knauer</td>
</tr>
<tr>
<td>Susanne</td>
<td>Kilp</td>
</tr>
<tr>
<td>Katrina</td>
<td>Mealey</td>
</tr>
<tr>
<td>Michael</td>
<td>Myers</td>
</tr>
<tr>
<td>John</td>
<td>Merson</td>
</tr>
<tr>
<td>Jane</td>
<td>Owens</td>
</tr>
<tr>
<td>Kari</td>
<td>Riggs</td>
</tr>
<tr>
<td>Kelly</td>
<td>Rosenkrans</td>
</tr>
<tr>
<td>Kristen</td>
<td>Stout-Diffenderfer</td>
</tr>
<tr>
<td>Lisa</td>
<td>Troutman</td>
</tr>
<tr>
<td>Hailey</td>
<td>Yancy</td>
</tr>
</tbody>
</table>

AHI MDR1 Working Group

FDA
Animal Health Institute
Boehringer Ingelheim Animal Health
Exponent
Zoetis
MSD
Washington State University
FDA
Consultant
Elanco
Animal Health Institute
FDA
The information and details provided in this report are proprietary and contain information provided in confidence by Wiley to the editorial team. It is understood that both parties shall treat the contents of this report in strict confidence in perpetuity. © 2022 Wiley
Increasing your impact with open research

The funding environment is changing rapidly, with increasing requirements for data and research findings to be openly available to all. We work closely with researchers, funders, societies and institutions to ensure research is easily discoverable by the people who need it.

Open access: Making research available to everyone

By removing the barriers to published research, open access makes research findings available to everyone — driving forward the pace and strength of global innovation and invention.

In 2021, we celebrated 10 years since the launch of our gold open access program. We started with 2 gold OA titles in 2011, growing rapidly to 233 in 2021. Acquiring Hindawi added a further 220 gold OA journals.

90% of Wiley journals now offer an open access publishing option. That's 1,400 journals across 120 subjects.

In 2021, gold and hybrid open access articles accounted for almost a third of all the articles we published – in all a total of 70k articles, 15k more than in 2020.

Open Access Week in October focused on the theme of “It Matters How We Open Knowledge: Building Structural Equity”. Read our thoughts on The Wiley Network, including looking back at the past 10 years, predicting forwards to the next 10, and the researcher view on open access.

Advantages of publishing open access

We undertook an extensive review of the impact of Wiley-published journal articles from 2015-2021. See our infographic and white paper on the advantages of open access publication.

Click here to see the full infographic.

Easier research recognition for open access funding

Open access continues to drive changes in how we publish. Over decades of growth, our journals had defined an incredible 29,000 different article types.

With so many transformational arrangements in place, article categorization has a new importance in recognizing eligibility for open access funding. The development, implementation, and benefits of concise publishing taxonomy: Article Type Harmonization describes our new taxonomy of 30 article types and the benefits we expect everyone to see.

Open data: Maximizing the value of research

We're committed to facilitating research discovery by encouraging the sharing of research data, methodology and reporting standards, enabling researchers to analyze and reuse data to further discovery.

Our open data strategy recommends adopting 'expects data sharing' as journal policy, where a data availability statement is included with the article, explaining where and how people can access the data or why it isn't sharable. Wiley publishes 756 journals that expect data sharing and 63 journals that now mandate data sharing.

Easier research recognition for open access funding

Open access continues to drive changes in how we publish. Over decades of growth, our journals had defined an incredible 29,000 different article types.

With so many transformational arrangements in place, article categorization has a new importance in recognizing eligibility for open access funding. The development, implementation, and benefits of concise publishing taxonomy: Article Type Harmonization describes our new taxonomy of 30 article types and the benefits we expect everyone to see.

Open data: Maximizing the value of research

We're committed to facilitating research discovery by encouraging the sharing of research data, methodology and reporting standards, enabling researchers to analyze and reuse data to further discovery.

Our open data strategy recommends adopting 'expects data sharing' as journal policy, where a data availability statement is included with the article, explaining where and how people can access the data or why it isn't sharable. Wiley publishes 756 journals that expect data sharing and 63 journals that now mandate data sharing.

Open Science Badges incentivize researchers to highlight shared data and materials, signaling to readers that more information is available. The badges were developed by the Center for Open Science and are available for use in articles on Wiley Online Library.

Open practices: Enabling collaboration and transparency

As research becomes more open, publishing processes must also become more transparent. Open processes enable greater trust in published research and increase accountability. Our commitment to this means exploring big changes to the publishing process.

In 2021, 75 journals took part in our transparent peer review pilot in collaboration with Publons and ScholarOne. 12,700 articles have now been published with transparent peer review content.

56 journals offer Registered Reports, where study methodologies are peer reviewed and accepted or rejected based on the research question and proposed methodology before the research takes place. Registered Reports improve studies before data are collected and reinforce the fact that positive or negative results add to our knowledge.

As more funders require early accessibility of research findings, researchers are sharing their work on preprint servers before submitting to a journal for peer review. Under Review from Authorea and Overleaf are ideal for researchers to share ideas, create papers, edit documents, and make changes. Authors can then share their research early – providing benefits including earlier views, citations and collaboration opportunities.

A commitment to research integrity

Our commitment to improving research integrity means working together to protect the integrity of research and the reproducibility of data. Wiley's Integrity in Publishing Group comprises over 40 experts from our editorial, content, and legal teams, who provide support and advice for Wiley colleagues, editors, and societies on best practice in research publishing, in line with Wiley’s Best Practice Guidelines and COPE.

CRediT recognizes the role each person played to create the published research. In its second year, 172 Wiley journals are using CRediT, with the highest uptake in life sciences and medicine.
Authors, editors, and reviewers alike are eager for change that creates a more streamlined publishing process while upholding the highest standards of quality. We’ve listened to researcher experiences and developed tech-based solutions to reimagine the publishing process.

Making publishing work better, for everyone

Our continuous improvement approach means that a typical article can now publish in 20 days — with an increasing percentage of articles publishing under 18 days.

The introduction of AI tools for article book-in enables us to greatly reduce the number of author queries at the proofing stage, streamlining the process and delivering an improved author experience.

Version 2.0 of our HTML proofing system went live in early 2022, bringing improved functionality and crisper rendering of math and equations. It rolls out to all eligible titles this year.

To better showcase authors’ research, we are providing support for large images and deep zoom through the article figure viewer on Wiley Online Library, as well as video and audio capabilities for 3D images, and enhanced article-level metrics.

Simplifying the submission process

Research suggests that, on average, it takes an author 14 hours to format their manuscript ready for submission. We are reducing this time and effort with two key initiatives designed to improve the author experience — ReX and free-format submission.

More than 280 journals now use our smart submission platform ReX, and over 100k new submissions have come via this route since its launch. Watch this video to see how ReX is making submission easier for everyone.

350 journals now offer free-format submission, which simplifies the submission process by saving the journal-specific formatting to the revision stage. This improves both the author experience and your journal’s reputation in the community. Learn more here.

Transfer networks – helping research find the right journal

More than half of the journals we publish now participate in an editor-driven transfer network or use our automated Transfer Desk Assistant (TDA). TDA provides a transfer service to authors of approximately 17,000 rejected manuscripts per month.

We heard that you’d like more information on transfer networks and how they help the researcher community find a home for all valuable research. Our blog and video show four key benefits of transfers.

An expanded range of services for authors

Wiley Editing Services offers authors a range of services that help them to prepare their article for submission and promote it post-publication. Several societies have chosen to invest funds to cover a specific aspect of post-publication activity for their authors, including infographics and lay summaries, and are seeing authors benefit from this decision.

Building an engaged reviewer pool

To decrease the burden on editors to find reviewers, we piloted a Reviewer Selection service on a small number of journals, to expand the reviewer database and reduce the average time to decision. We hope to scale up the service in 2022.

We sent over 360,000 certificates of appreciation to reviewers at over 700 journals in 2021. Nearly 2.2 million reviews for over 1,100 Wiley journals have been recorded on Publons, for more than 370,000 reviewers, where they can be used to support grant applications.

Enabling easier access to research

We’re building on our successful GetFTR pilot, which makes it easy for researchers to access direct, authenticated content across different publishers.

Starting early in 2022, we are also trialling a 6-month project to make 70,000 organic chemistry articles across different publishers available in one central hub. Learn more here.

Wiley Content Sharing facilitates research collaboration by providing subscribers with a simple tool for sharing free-to-read full-text articles with non-subscribers. In 2021, researchers accessed articles over 99k times through this functionality.

Wiley Author Sharing enables authors to generate a link of the full text of their published articles that they can share with an unlimited number of people for non-commercial personal use. There were nearly 200k downloads of shared articles in 2021.
Driving a sustainable route to open access

Driving a sustainable route to open access

Working with future-focused partners we are driving change in the industry through new publishing models. Transformational agreements are transforming scholarly publishing so that researchers at affiliated institutions benefit from access to the millions of articles their subscriptions previously paid for, whilst also funding their open access publishing.

Demand for open access publishing agreements continues to increase. We’re at the forefront of negotiating national agreements that deliver open access options at scale whilst managing the transition to open in a sustainable way. These agreements also secure access for your journal in the top institutions, which ensures the highest possible exposure.

From 2020 to 2021 – the difference of a year

Last year, we were negotiating new transformational arrangements across Europe, in countries including Italy and Switzerland. Those agreements are now signed and active. We were also in the early stages of discussions with governments and consortia elsewhere in the world beyond Europe. This year, as well as four new arrangements in Europe, we now have transformational arrangements in Austria, Finland, Germany, Hungary, Ireland, Italy, Sweden, Switzerland, The Netherlands and the UK.

In January 2022 we added Slovenia to this list, bringing the total eligible institutions across Europe to 1,230.

Jisc – embedding the open access agreement

We continued to see unprecedented submission numbers from our authors in the UK. We have been working very closely with Jisc to ensure that in 2022 more UK authors than ever before will be able to publish their research open access, throughout the year.

Projekt DEAL – three years of success

We extended our current successful agreement to last throughout 2022. After 3 years of our ground-breaking new partnership with Projekt DEAL, we can see its influence in terms of article publication – with more than 10,000 open access articles published annually – and an increase of 50% usage in Germany. More detail on aims and achievements here.

Increasing open access interest across the US

We have seen a marked increase in interest in negotiating open access agreements across North America. We now have seven transformational agreements in place, up from two (Iowa State University and Johns Hopkins University) last year.

Starting in 2022, transformational agreements with the following organizations are all live:

- Texas State University, US Department of Energy,
- Carnegie Mellon University,

This means that transformational deals now include 104 US institutions, which we anticipate will cover over 2.5k articles publishing gold open access.

First transformational agreements in Asia-Pacific and the Middle East

In October 2021, we signed our first two agreements in Australia and New Zealand — with CAUL and CSIRO. CAUL covers 52 institutions and is expected to have an output of 6k articles.

January 2022 brought further agreements — the Republic of Korea with NST on behalf of 25 institutions, and our first agreement in the Middle East, in Israel with MALMAD, covering 24 institutions.
The development and rollout of a COVID vaccine in such a short space of time is a triumph that demonstrates the central contributions of science to the welfare of mankind. It showcases the power of bringing different skills and communities together to address a common goal.

Sharing COVID research quickly and widely

COVID research published by Wiley continued to be shared via the World Health Organization, with over 1,600 articles now included. Likewise, we continued to deposit all existing and forthcoming COVID research into PubMedCentral, as well as making the articles freely available via Wiley Online Library on our COVID-19 research hub.

Communicating research outcomes

We're committed to supporting science and bridging the communications gap between research, the media, and the public.

In 2021, we held five Wiley Science Talks in partnership with the World Federation of Science Journalists to connect societies and researchers directly with the journalists that share their research. These sessions encourage evidence-based journalism, enhance accuracy of science news coverage, and enable discovery and understanding of the latest research.

In June, our podcast This Study Shows returned for a third series, sharing the fascinating stories of people who are changing the world with their science communication. It also launched a new spotlight series meeting the scientists behind research that made headlines, and their journey to publish their work.

This Study Shows has now shared contributions from 50 leading experts to over 13,000 listeners. Find it wherever you normally get your podcasts — direct links here.

Environmental sustainability: reducing our climate impact

We've been looking closely at our climate impact. Print journal makes up a big part of Wiley's carbon impact, so we launched our Go Green Fund to plant a tree for every journal copy that we stop printing.

We've set a target of planting 1m trees over the next 3 years and are on track to meet this ambitious target, having planted 200,000 trees in the first six months since launch.

A further 90 titles moved online-only from the start of 2022, meaning that over 50% of journals published by Wiley are now online-only.

We also focused on plastic pollution and targeted the removal of plastic packaging. All titles printed in the UK moved to paper packaging, eliminating 1.3m plastic bags. Over 60% of our titles now ship with either no packaging at all or in paper envelopes. We are exploring options for the rest.

Learn about your journal’s sustainability with our Carbon Footprint calculator, which helps to identify the carbon footprint of a print journal. For more information speak to your Journal Manager.

In fiscal year 2021 we again achieved Carbon Neutral Certification for our operations and consumed 100% renewable energy for all locations. In 2022, we will focus on shrinking our environmental footprint further, including optimizing materials used in production and working with vendors to minimize environmental impact.

Tackling equity issues in our community

We know that members want publishers and societies to work together on DE&I initiatives. We're still listening and learning in order to take the right and important steps for our communities and future community members. Some of the initial steps we've taken so far include:

• Continuing our collaboration with 48 publishers and societies in the Joint Commitment for Action on Inclusion and Diversity in Publishing; committed to understanding and reflecting our research communities and developing standards and processes for collection of self-reported data.

• Launching RISE (Research in Support of Equity), providing free-to-access curated collections around the topic of social equity. For example, see the curated collection ‘Diversifying Museums’.

• We promoted awareness of underrepresented research communities by supporting initiatives such as @BlackinChem and @BlackinNeuro.

• We supported our author community by updating our author name change policy to support anonymity of authors who wish to change their name on already-published research, introducing author pronoun capability to Wiley Online Library, and enabling authors to select the ‘Mx’ honorific in their account details on many of our submission systems.

• We provided thought leadership via articles on the Wiley Network exploring ways to improve inclusion in our journal practices.

• DE&I experts collaborated with us for colleague training and Virtual Seminars.

We are your partner in this as in everything else, and we look forward to taking our next steps on this important journey.
Readership

This chart shows the increase in the number of full-text article downloads for the *Journal of Veterinary Pharmacology and Therapeutics* in the period 2012 to 2021. The total includes usage on Wiley Online Library, PubMed, and other third-party databases. Downloads via Wiley Online Library increased (22.4%) in 2021. This compares with an increase (30.9%) across all Wiley journals in the Veterinary Medicine subject area.

The global reach of the *Journal of Veterinary Pharmacology and Therapeutics* is reflected in its readership, as displayed by this chart showing the origin of full-text downloads of the *Journal of Veterinary Pharmacology and Therapeutics* on Wiley Online Library. The darkest shading shows where readership of the *Journal of Veterinary Pharmacology and Therapeutics* is highest.

This chart shows the top 10 countries from which articles in the *Journal of Veterinary Pharmacology and Therapeutics* were downloaded via Wiley Online Library in 2021, and the percentage each country contributed to total usage. All other countries/regions are combined under "Others."*
Readership

Most downloaded articles on Wiley Online Library

<table>
<thead>
<tr>
<th>Rank</th>
<th>Author(s)</th>
<th>Article Title</th>
<th>Volume</th>
<th>Issue</th>
<th>No. of Accesses</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mohammad-Zadeh, L. et al.</td>
<td>Serotonin: a review</td>
<td>31</td>
<td>3</td>
<td>8,671</td>
</tr>
<tr>
<td>2</td>
<td>Burch, D. &amp; Sperling, D.</td>
<td>Amoxicillin—current use in swine medicine</td>
<td>41</td>
<td>3</td>
<td>4,756</td>
</tr>
<tr>
<td>3</td>
<td>Baggot, J.</td>
<td>Pharmacokinetic terms: symbols and units</td>
<td>24</td>
<td>2</td>
<td>4,416</td>
</tr>
<tr>
<td>4</td>
<td>Zhou, X. et al.</td>
<td>Current review of isoxazoline ectoparasiticides used in veterinary medicine</td>
<td>45</td>
<td>1</td>
<td>3,755</td>
</tr>
<tr>
<td>5</td>
<td>Goetting, V. et al.</td>
<td>Pharmacokinetics of veterinary drugs in laying hens and residues in eggs: a review of the literature</td>
<td>34</td>
<td>6</td>
<td>3,111</td>
</tr>
<tr>
<td>6</td>
<td>Davis, J. et al.</td>
<td>Pharmacokinetics, pharmacodynamics and clinical use of trazodone and its active metabolite m-chlorophenylpiperazine in the horse</td>
<td>41</td>
<td>3</td>
<td>2,680</td>
</tr>
<tr>
<td>7</td>
<td>Lees, P. et al.</td>
<td>A history of antimicrobial drugs in animals: Evolution and revolution</td>
<td>44</td>
<td>2</td>
<td>2,282</td>
</tr>
<tr>
<td>8</td>
<td>Toutain, P. et al.</td>
<td>The pharmacokinetic/pharmacodynamic paradigm for antimicrobial drugs in veterinary medicine: Recent advances and critical appraisal</td>
<td>44</td>
<td>2</td>
<td>2,018</td>
</tr>
<tr>
<td>9</td>
<td>Sartini, I. &amp; Giorgi, M.</td>
<td>Grapiprant: A snapshot of the current knowledge</td>
<td>44</td>
<td>5</td>
<td>1,698</td>
</tr>
<tr>
<td>10</td>
<td>Gonzales, A. et al.</td>
<td>Oclacinilb (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy</td>
<td>37</td>
<td>4</td>
<td>1,626</td>
</tr>
</tbody>
</table>

This table includes details of the 10 most-downloaded articles of 2021. The average number of downloads per article published in the *Journal of Veterinary Pharmacology and Therapeutics* in 2021 was 262. Across all journals that Wiley publishes in the same subject area, the average number of downloads per article was 685.

Top referrers

<table>
<thead>
<tr>
<th>Rank</th>
<th>Referrer Service</th>
<th>% of Downloads</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Google Search</td>
<td>25.6%</td>
</tr>
<tr>
<td>2</td>
<td>Google Scholar</td>
<td>18.1%</td>
</tr>
<tr>
<td>3</td>
<td>Institutions and Library Services</td>
<td>3.3%</td>
</tr>
<tr>
<td>4</td>
<td>PubMed/PMC</td>
<td>2.8%</td>
</tr>
<tr>
<td>5</td>
<td>Bing</td>
<td>1.5%</td>
</tr>
</tbody>
</table>

Open search continues to play a key role in driving readership. This table shows the top 5 known referrers, and the % of total downloads resulting from each.

Article downloads via Wiley Content Sharing

In 2021, 51 sharing links were generated via the Wiley Content Sharing service, resulting in 31 full-text downloads. In addition, links shared by authors resulted in 7 downloads. Links shared by media sites generated a further 6 downloads.
Author Experience: Submissions

Accepted and rejected articles

The total number of submissions in 2021 decreased (-7.6%) compared with 2020. This compares with an increase (4.8%) across all Wiley journals in the Veterinary Medicine subject area.

New submissions by type

The total number of submissions in 2021 decreased (-7.6%) compared with 2020. This compares with an increase (4.8%) across all Wiley journals in the Veterinary Medicine subject area.

Accepted and rejected articles by type

This chart shows the number of accepted and rejected articles by article type.

Transfers/referrals

In 2021, 62.4% of the papers rejected by your journal were offered an option to transfer to another journal. 88 were offered to transfer to another journal because of an editor referral, and so far, 80 of those transfer offers were agreed by the author and sent to another journal in your transfer network in ScholarOne.

Quantity and speed of reviews

This chart shows review data for original submissions only for the past five years. Additionally, 207 reviews were claimed on Publons in 2021 by 86 reviewers, a 52.4% uptake.

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of review invitations sent</td>
<td>934</td>
<td>901</td>
<td>816</td>
<td>894</td>
<td>608</td>
</tr>
<tr>
<td>Number of reviews invitations accepted</td>
<td>552</td>
<td>511</td>
<td>473</td>
<td>534</td>
<td>375</td>
</tr>
<tr>
<td>Number of reviews completed</td>
<td>515</td>
<td>480</td>
<td>467</td>
<td>517</td>
<td>364</td>
</tr>
<tr>
<td>Median days to review completion</td>
<td>12</td>
<td>11</td>
<td>12</td>
<td>11</td>
<td>11</td>
</tr>
</tbody>
</table>
**Author Experience: Submissions**

### Speed of review process

Includes all articles, including those that were rejected without peer review

<table>
<thead>
<tr>
<th>Median number of days (min-max)</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Submission to first decision</td>
<td>43 (1-229)</td>
<td>28 (1-182)</td>
<td>6 (1-205)</td>
<td>12 (1-279)</td>
<td>7 (1-203)</td>
</tr>
<tr>
<td>Submission to final decision</td>
<td>84 (1-493)</td>
<td>57 (1-647)</td>
<td>6 (1-279)</td>
<td>8 (1-371)</td>
<td>4 (1-270)</td>
</tr>
<tr>
<td>Submission to acceptance</td>
<td>148 (41-493)</td>
<td>120 (9-362)</td>
<td>96 (22-279)</td>
<td>104 (7-371)</td>
<td>92 (1-270)</td>
</tr>
</tbody>
</table>

Articles are included in the year the decision was made, and data includes all articles, whether or not they were sent out to peer review. The number of days from submission to acceptance in 2021 was a median of 92 days, down from 104 days in 2020. This compares with a median of 132 in 2021 across all Wiley journals in the Veterinary Medicine subject area.

Excluding articles that were rejected without peer review

<table>
<thead>
<tr>
<th>Median number of days (min-max)</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Submission to first decision</td>
<td>54 (1-229)</td>
<td>45 (5-182)</td>
<td>37 (5-205)</td>
<td>40 (3-279)</td>
<td>46 (7-203)</td>
</tr>
<tr>
<td>Submission to final decision</td>
<td>118 (9-493)</td>
<td>110 (5-647)</td>
<td>81 (10-279)</td>
<td>93 (3-371)</td>
<td>82 (8-270)</td>
</tr>
<tr>
<td>Submission to acceptance</td>
<td>148 (41-493)</td>
<td>121 (35-362)</td>
<td>96 (22-279)</td>
<td>104 (7-371)</td>
<td>111 (8-270)</td>
</tr>
</tbody>
</table>

Articles are included in the year the decision was made, and data excludes articles that were rejected without review. The number of days from submission to acceptance in 2021 was a median of 111 days, up from 104 days in 2020. This compares with a median of 135 in 2021 across all Wiley journals in the Veterinary Medicine subject area.

### Country of submission

This chart shows the top 15 countries ranked by the number of submissions to the journal. All submissions counted were submitted in 2021. The remaining countries are grouped into “Others.”